

Open Peer Review on Qeios

Anti-AXL Fusion Protein AVB-S6-500

National Cancer Institute

Source

National Cancer Institute. <u>Anti-AXL Fusion Protein AVB-S6-500</u>. NCI Thesaurus. Code C156017.

A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, AXL Fc fusion protein AVB-S6-500 selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.

Qeios ID: BRI9FT · https://doi.org/10.32388/BRI9FT